17 December 2007
Choroidal neovascularisation secondary to rubella retinopathy
Hakki BirinciCase Rep Clin Pract Rev 2007; 8:353-356 :: ID: 628167
Abstract
Background: A case of rubella retinopathy associated with subfoveal choroidal neovascularisation (CNV) is presented.
Case Report: A 9-year-old girl with subfoveal choroidal neovascularisation in left eye secondary to rubella retinopathy was treated with photodynamic therapy (PDT) usin verteporfi n. The patient was hearing-impaired. Patient was followed up with fundus examinations, fundus fl uorescein angiography (FFA), and best-corrected visual acuity. Three treatments of photodynamic therapy using verteporfi n and one dose triamcinolone acetonide intavitreal injection were applied. Owing to recurrence of active choroidal neovascularisation the patient required three treatments of photodynamic therapy in the next 1 year. Although there was a decrease in the size of lesion as a result of photodynamic therapy, recurrence developed after each treatment, and fi nally, disciform scarring occurred with fi brosis.
Conclusions: Subfoveal choroidal neovascularisation may develop secondary to rubella retinopathy. Photodynamic therapy may be an effective treatment for subfoveal choroidal neovascularisation secondary to rubella retinopathy in early stage cases.
Keywords: hemiangiopericytoma, meningeal tumor, computed tomography, magnetic, resonance imaging
347
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.944665
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946514
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946456
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945602
Most Viewed Current Articles
21 Jun 2024 : Case report
90,010
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
50,284
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
25,908
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,715
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030